TH104 for itching in primary biliary cholangitis
Part of Digestive system, Skin clinical trials.
This trial tests a new medication, TH104, to see if it can reduce itching caused by primary biliary cholangitis (PBC). Itching is a common symptom of PBC, and this study aims to find a more effective treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with primary biliary cholangitis (PBC).
- You have moderate to severe itching (a score of 5 or higher on a 0-10 scale) on most days.
- You are not pregnant or breastfeeding, and you are willing to use birth control if needed.
- You have not had serious liver complications like belly fluid, confusion, or bleeding from the esophagus.
- You have not taken opioid pain medications in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.
This trial tracks how well the combination of ursodiol and seladelpar works in people with primary biliary cholangitis (PBC), a liver disease. It aims to see if this treatment helps control symptoms and liver function.
This trial tests whether adding fenofibrate to ursodeoxycholic acid (UDCA) can improve liver test results in people with primary biliary cholangitis (PBC) who did not respond enough to UDCA alone. It aims to see if the combination works better and is safe for adults with persistent, abnormal liver markers.
This trial looks at whether slowly reducing UDCA (a medication for primary biliary cholangitis) is safe and still helpful in people whose liver tests have improved. It may help some patients avoid higher doses if their disease is well controlled.
This trial tests a special light treatment (photobiomodulation) to see if it can safely reduce itch. It compares the treated area to a similar untreated area on your body.
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
Hear when a new Pruritus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.